Onconic Therapeutics Inc. (KOSDAQ:476060)

South Korea flag South Korea · Delayed Price · Currency is KRW
21,250
-650 (-2.97%)
Apr 30, 2026, 3:30 PM KST
Market Cap953.87B +257.8%
Revenue (ttm)53.39B +259.8%
Net Income15.78B
EPSn/a
Shares Out44.89M
PE Ratio60.43
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume462,542
Average Volume477,709
Open21,800
Previous Close21,900
Day's Range20,600 - 21,800
52-Week Range5,000 - 28,900
Betan/a
RSI45.84
Earnings DateMar 20, 2026

About Onconic Therapeutics

Onconic Therapeutics Inc. engages in the research and development of anti-cancer therapy in South Korea. It develops Zastaprazan (OCN-101), a potassium-competitive acid blocker, which is in phase 3 for the treatment of gastric acid related disease; and OCN-201 (JPI-547), an anticancer drug; JP-1366, a treatment for peptic ulcer; and drugs for DDR and immuno-oncology fields. JP-1366, a poly ADP-ribose polymerase inhibitor, which is in phase 1 for the treatment of pancreatic cancer. The company was founded in 2020 and is based in Seoul, South Kor... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 476060
Full Company Profile

Financial Performance

Financial Statements